Novavax Cash Per Share from 2010 to 2024

NVAX Stock  USD 18.17  1.39  7.11%   
Novavax Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Novavax Cash Per Share regression line of annual values had r-squared of  0.03 and arithmetic mean of  10.92. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
5.74516712
Current Value
8.84
Quarterly Volatility
5.92828056
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 97.33. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Novavax over the last few years. It is Novavax's Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 16.31 X10 Years Trend
Pretty Stable
   Cash Per Share   
       Timeline  

Novavax Cash Per Share Regression Statistics

Arithmetic Mean10.92
Geometric Mean9.21
Coefficient Of Variation54.28
Mean Deviation5.19
Median10.75
Standard Deviation5.93
Sample Variance35.14
Range17.1413
R-Value0.17
Mean Square Error36.70
R-Squared0.03
Significance0.54
Slope0.23
Total Sum of Squares492.02

Novavax Cash Per Share History

2024 8.84
2023 5.75
2022 17.1
2021 20.36
2020 12.35
2019 3.27
2018 4.98

About Novavax Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novavax income statement, its balance sheet, and the statement of cash flows. Novavax investors use historical funamental indicators, such as Novavax's Cash Per Share, to determine how well the company is positioned to perform in the future. Although Novavax investors may use each financial statement separately, they are all related. The changes in Novavax's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novavax's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novavax Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 5.75  8.84 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.